Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANEB Anebulo Pharmaceuticals	$2.40 +0.8%	$1.92	$0.80 ▼ $3.42	$97.78M	-0.88	1.18 million shs	41,063 shs
COYA Coya Therapeutics	$6.20 +1.1%	$5.96	$4.65 ▼ $10.24	$102.52M	0.26	67,223 shs	38,667 shs
CRBP Corbus Pharmaceuticals	$9.59 +7.0%	$8.54	$4.64 ▼ $61.89	$109.81M	3.2	114,943 shs	154,112 shs
IGC IGC Pharma	$0.36 +10.1%	$0.34	$0.25 ▼ $0.48	$30.83M	1.48	913,992 shs	214,616 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANEB Anebulo Pharmaceuticals	+0.84%	-11.11%	+49.07%	+137.62%	+29.73%
COYA Coya Therapeutics	+1.14%	-3.13%	+0.65%	+5.62%	+20.62%
CRBP Corbus Pharmaceuticals	+7.03%	+5.27%	+14.71%	+33.01%	-81.90%
IGC IGC Pharma	+3.46%	+5.28%	-2.45%	+22.53%	-11.45%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership
ANEB Anebulo Pharmaceuticals	2.1989 of 5 stars	3.3	3.0	0.0	2.8	1.7
COYA Coya Therapeutics	2.0359 of 5 stars	3.5	3.0	0.0	2.3	0.8
CRBP Corbus Pharmaceuticals	4.3078 of 5 stars	3.6	3.0	4.7	2.8	2.5
IGC IGC Pharma	1.7511 of 5 stars	3.5	0.0	0.0	1.9	1.7

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANEB Anebulo Pharmaceuticals	2.50	Moderate Buy	$5.50	129.17% Upside
COYA Coya Therapeutics	3.00	Buy	$16.50	166.13% Upside
CRBP Corbus Pharmaceuticals	3.10	Buy	$49.00	410.95% Upside
IGC IGC Pharma	3.00	Buy	$3.88	979.39% Upside

Current Analyst Ratings Breakdown

Latest IGC, CRBP, ANEB, and COYA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	COYA Coya Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
8/13/2025	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00
8/6/2025	CRBP Corbus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$56.00 ➝ $53.00
7/30/2025	CRBP Corbus Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$28.00
7/24/2025	COYA Coya Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
7/23/2025	ANEB Anebulo Pharmaceuticals	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/12/2025	CRBP Corbus Pharmaceuticals	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/9/2025	COYA Coya Therapeutics	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$16.00
7/1/2025	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00
6/9/2025	COYA Coya Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
5/15/2025	ANEB Anebulo Pharmaceuticals	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $3.00

(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANEB Anebulo Pharmaceuticals	N/A	N/A	N/A	N/A	$0.15 per share	N/A
COYA Coya Therapeutics	$3.55M	29.22	N/A	N/A	$2.37 per share	2.62
CRBP Corbus Pharmaceuticals	N/A	N/A	N/A	N/A	$9.06 per share	N/A
IGC IGC Pharma	$1.27M	25.65	N/A	N/A	$0.08 per share	4.49

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANEB Anebulo Pharmaceuticals	-$8.20M	-$0.26	N/A	∞	N/A	N/A	-90.11%	-84.53%	9/24/2025 (Estimated)
COYA Coya Therapeutics	-$14.88M	-$1.07	N/A	N/A	N/A	N/A	-48.88%	-43.32%	N/A
CRBP Corbus Pharmaceuticals	-$40.21M	-$4.76	N/A	N/A	N/A	N/A	-43.65%	-39.62%	N/A
IGC IGC Pharma	-$13M	-$0.08	N/A	N/A	N/A	-714.16%	-122.44%	-88.40%	N/A

Latest IGC, CRBP, ANEB, and COYA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	COYA Coya Therapeutics	-$0.22	-$0.36	-$0.14	-$0.36	$0.78 million	$0.16 million
8/5/2025	Q2 2025	CRBP Corbus Pharmaceuticals	-$1.55	-$1.44	+$0.11	-$1.44	N/A	N/A
5/13/2025	Q3 2025	ANEB Anebulo Pharmaceuticals	-$0.05	-$0.04	+$0.01	-$0.04	N/A	N/A
5/13/2025	Q1 2025	COYA Coya Therapeutics	-$0.44	-$0.44	N/A	-$0.44	$2.63 million	$257.88 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANEB Anebulo Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
COYA Coya Therapeutics	N/A	N/A	N/A	N/A	N/A
CRBP Corbus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IGC IGC Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANEB Anebulo Pharmaceuticals	N/A	25.29	25.29
COYA Coya Therapeutics	N/A	8.84	8.84
CRBP Corbus Pharmaceuticals	N/A	9.21	9.21
IGC IGC Pharma	0.02	1.15	0.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANEB Anebulo Pharmaceuticals	28.40%
COYA Coya Therapeutics	39.75%
CRBP Corbus Pharmaceuticals	64.64%
IGC IGC Pharma	3.87%

Insider Ownership

Company	Insider Ownership
ANEB Anebulo Pharmaceuticals	80.60%
COYA Coya Therapeutics	12.00%
CRBP Corbus Pharmaceuticals	4.00%
IGC IGC Pharma	31.48%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANEB Anebulo Pharmaceuticals	4	41.08 million	7.97 million	Not Optionable
COYA Coya Therapeutics	6	16.73 million	14.72 million	Not Optionable
CRBP Corbus Pharmaceuticals	40	12.26 million	11.77 million	Optionable
IGC IGC Pharma	61	90.81 million	54.60 million	N/A

IGC, CRBP, ANEB, and COYA Headlines

Recent News About These Companies

IGC Pharma, Inc.: IGC Pharma Highlights Alzheimer's Pipeline with Encouraging Preclinical Data on IGC-M3 and Advancing Phase 2 Cannabinoid-Based IGC-AD1

August 13 at 7:47 AM | finanznachrichten.de

IGC Pharma highlights preclinical data on IGC-M3

August 12 at 4:43 PM | msn.com

IGC Pharma Highlights Alzheimer's Pipeline with Encouraging Preclinical Data on IGC-M3 and Advancing Phase 2 Cannabinoid-Based IGC-AD1

August 12 at 9:00 AM | accessnewswire.comA

IGC Pharma Reports IGC-M3's In Vitro Efficacy Against Alzheimer's - Targeting key Drivers of Disease Progression

August 5, 2025 | accessnewswire.comA

IGC Pharma to Present Advanced AI Platforms for Alzheimer's Disease at the AAIC 2025

July 23, 2025 | accessnewswire.comA

IGC Pharma's Principal Scientist Dr. Jagadeesh Rao Receives Best Researcher Award at 11th Annual World Neuroscience Awards

July 21, 2025 | accessnewswire.comA

IGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict ...

July 12, 2025 | morningstar.comM

IGC Pharma, Inc.: IGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict Alzheimer's Risk and Accelerate Early Detection

July 11, 2025 | finanznachrichten.de

IGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict Alzheimer's Risk and Accelerate Early Detection

July 10, 2025 | accessnewswire.comA

Earnings call transcript: IGC Pharma Q2 2025 sees strategic growth in Alzheimer’s research - Investing.com

July 2, 2025 | investing.com

IGC Pharma earnings matched, revenue fell short of estimates

July 2, 2025 | investing.com

Earnings call transcript: IGC Pharma Q2 2025 sees strategic growth in Alzheimer’s research - Investing.com UK

July 2, 2025 | uk.investing.com

IGC Pharma, Inc.: IGC Pharma: Fiscal Year 2025 Financial and Operational Highlights - A Year of Transformative Progress in Alzheimer's Innovation

June 30, 2025 | finanznachrichten.de

IGC Pharma: Fiscal Year 2025 Financial and Operational Highlights - A Year of Transformative Progress in Alzheimer's Innovation

June 30, 2025 | accessnewswire.comA

IGC Pharma, Inc.: IGC Pharma to Host Fiscal Year-End 2025 Shareholder Update Call on Monday June 30, 2025 - FinanzNachrichten.de

June 28, 2025 | finanznachrichten.de

IGC Pharma to Host Fiscal Year-End 2025 Shareholder Update Call on Monday June 30, 2025 - Morningstar

June 28, 2025 | morningstar.comM

IGC Pharma Inc Trailing Returns - Morningstar

June 27, 2025 | morningstar.comM

IGC Pharma Inc. Annual Cash Flow Statement - MarketWatch

June 27, 2025 | marketwatch.com

Insights Ahead: IGC Pharma's Quarterly Earnings

June 27, 2025 | benzinga.com

IGC Pharma, Inc. (IGC) Reports Q4 Loss, Beats Revenue Estimates

June 27, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IGC, CRBP, ANEB, and COYA Company Descriptions

Anebulo Pharmaceuticals NASDAQ:ANEB

$2.40 +0.02 (+0.84%)

Closing price 08/13/2025 04:00 PM Eastern

Extended Trading

$2.38 -0.02 (-0.63%)

As of 08/13/2025 04:10 PM Eastern

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

Coya Therapeutics NASDAQ:COYA

$6.20 +0.07 (+1.14%)

Closing price 08/13/2025 04:00 PM Eastern

Extended Trading

$6.19 -0.01 (-0.16%)

As of 08/13/2025 06:52 PM Eastern

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

Corbus Pharmaceuticals NASDAQ:CRBP

$9.59 +0.63 (+7.03%)

Closing price 08/13/2025 04:00 PM Eastern

Extended Trading

$9.54 -0.04 (-0.47%)

As of 08/13/2025 05:13 PM Eastern

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

IGC Pharma NYSEMKT:IGC

$0.36 +0.03 (+10.09%)

Closing price 08/13/2025 03:58 PM Eastern

Extended Trading

$0.36 +0.00 (+0.28%)

As of 08/13/2025 07:56 PM Eastern

IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time